The Water Purifier That’s Drowning in Its Own Capex

Welcome to the Margin Trap That Purifies Water But Not Profits

Let’s talk about Ion Exchange (India). Yes, the company that fits resin columns into industrial water treatment plants. Yes, the one that sells ion exchange resins to semiconductor fabs, pharma labs, and the Government of India’s entire Jal Jeevan Mission. No, they don’t have an AI pivot. No, they’re not launching a demat app. They do water. In very technical ways. Boring, you think? Maybe. But a ₹4,900 crore market cap suggests otherwise.

Here’s the thing: Ion Exchange has completed over 100,000 installations worldwide. They have a ₹3,400 crore order book, a ₹8,200 crore pipeline, 36+ sales centers, and clientele that reads like a who’s-who of Indian industry—Reliance, NTPC, IOCL, CPCL. They serve majors like Taj Hotels, Oberoi, and Hyatt. Export presence across Africa, Japan, Middle East, Russia, Southeast Asia. Three revenue segments: Engineering (EPC, 58%), Chemicals (resins/adsorbents, 30%), and Consumer (bottled water filters, 12%).

But here’s the rub. In Q3 FY26 (Dec 2025), while revenue grew 6% YoY, operating profit fell 21% YoY. EBITDA margin compressed to 8%, down from double digits historically. Why? Three things hit at once: (1) A ₹400 crore greenfield resin plant in Roha started depreciating in Q3. (2) Engineering project delays and subdued international invoicing pushed out high-margin work. (3) The UP Jal Nigam project is executing at a crawl due to fund flow issues. Mix all three, and you get a company that’s simultaneously growing revenue while shrinking profits. Then, on Jan 29, 2026, the board slapped a ₹170 crore exceptional charge for labour code gratuity/leave provisions. Adjusted for that, the math works. But unadjusted, it’s a 50% profit compression quarter.

The market is already pricing it in—the stock fell 25% in one year. But management remains bullish, talking about Roha benefits kicking in from FY27, solar sector tailwinds, and semiconductor ultra-pure water as the next big leg. Concall tone: “This is the valley before the mountain.” Question is: how deep is the valley, and when does the climb start? Let’s find out.

They Treat Your Water. They’re Not Treating Their Own Balance Sheet.

Ion Exchange operates across three segments, and they’re as different as dal makhani, dosa, and masala chai—each claiming to be authentic Indian staple.

Segment 1: Engineering (58% of revenue, ₹425 Cr in Q3) — EPC (Engineering, Procurement, Construction) contracts. They build water treatment plants, desalination units, zero-liquid discharge (ZLD) systems, and sewage plants. Customers: industrial (NTPC, Reliance, IOCL), institutional (hotels, hospitals), and sovereign (UP Jal Nigam, Jal Jeevan Mission). In Q3, revenue was flat YoY, but profit fell 28% YoY. Why? Two words: execution timing. Large EPC projects are lumpy. High-value contracts got deferred to Q4. UP JJM funding remained “muted.” Management’s new stance: be picky about projects. Don’t chase unprofitable work. It sounds smart. But it’s also margin protection masquerading as strategy.

Segment 2: Chemicals (30% of revenue, ₹231 Cr in Q3) — This is where the real optionality lives. Ion Exchange makes ion exchange resins, specialty chemicals, and adsorbents. They sell to semiconductor fabs for ultra-pure water (UPW), pharma for purification, power plants for boiler feed water treatment. In Q3, revenue grew 16% YoY. But profit fell 18% YoY. Why? Product mix deterioration and—here’s the villain—the Roha resin plant. Commissioned in late September at 40–45% capacity, it’s now depreciating at full capex burden. Full capex on Roha: ~₹450 crore. Financed with ~₹345 crore term loan. Depreciation + interest now hitting Q3 P&L in full. Payback: 4–5 years. Expected utilization ramp: ~25% in FY27, full capacity in 4 years. The plant is a moonshot. But it’s expensive moonlight right now.

Segment 3: Consumer Products (12% of revenue, ₹99 Cr in Q3) — Water filters, purifiers, and drinking water solutions. Targets individuals, hotels, spas, hospitals, railways. In Q3, revenue grew 28% YoY (strong!), but the segment posted a ₹33 crore loss. Management doesn’t care. They’re reinvesting surpluses into brand building. “Bharat Ka Paani” campaign all over TV and sports. They’re betting that scale will eventually flip this segment profitable. It’s a long-term play. Question: does the market have patience? Early evidence: no.

Q3 FY26: The Numbers That Hurt More Than The Numbers

Result type: Quarterly Results  |  Q3 FY26 EPS: ₹1.38  |  Annualised EPS (Q3×4): ₹5.52  |  TTM EPS: ₹12.40

Fair Value Range: Between Hope and Reality